Cargando…
Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes
This review addresses appropriate patient selection for upadacitinib, a Janus kinase inhibitor approved by the FDA and EMA for treatment of moderately to severely active ulcerative colitis (UC). Janus kinase molecules can contribute to the inflammatory pathway, so inhibiting certain of them may prov...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007976/ https://www.ncbi.nlm.nih.gov/pubmed/36915649 http://dx.doi.org/10.2147/CEG.S367086 |
_version_ | 1784905651995017216 |
---|---|
author | Irani, Malcolm Fan, Christopher Glassner, Kerri Abraham, Bincy P |
author_facet | Irani, Malcolm Fan, Christopher Glassner, Kerri Abraham, Bincy P |
author_sort | Irani, Malcolm |
collection | PubMed |
description | This review addresses appropriate patient selection for upadacitinib, a Janus kinase inhibitor approved by the FDA and EMA for treatment of moderately to severely active ulcerative colitis (UC). Janus kinase molecules can contribute to the inflammatory pathway, so inhibiting certain of them may prove efficacious in treating UC and may reduce safety concerns. Upadacitinib is the newest Janus kinase inhibitor to be approved for UC, so it is timely and relevant to review patient selection and when to consider this medication. We will discuss efficacy and safety data from the pivotal clinical trials on upadacitinib. These data can be shared with patients and can inform the use of these agents in clinical practice. |
format | Online Article Text |
id | pubmed-10007976 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-100079762023-03-12 Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes Irani, Malcolm Fan, Christopher Glassner, Kerri Abraham, Bincy P Clin Exp Gastroenterol Review This review addresses appropriate patient selection for upadacitinib, a Janus kinase inhibitor approved by the FDA and EMA for treatment of moderately to severely active ulcerative colitis (UC). Janus kinase molecules can contribute to the inflammatory pathway, so inhibiting certain of them may prove efficacious in treating UC and may reduce safety concerns. Upadacitinib is the newest Janus kinase inhibitor to be approved for UC, so it is timely and relevant to review patient selection and when to consider this medication. We will discuss efficacy and safety data from the pivotal clinical trials on upadacitinib. These data can be shared with patients and can inform the use of these agents in clinical practice. Dove 2023-03-07 /pmc/articles/PMC10007976/ /pubmed/36915649 http://dx.doi.org/10.2147/CEG.S367086 Text en © 2023 Irani et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Irani, Malcolm Fan, Christopher Glassner, Kerri Abraham, Bincy P Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes |
title | Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes |
title_full | Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes |
title_fullStr | Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes |
title_full_unstemmed | Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes |
title_short | Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes |
title_sort | clinical evaluation of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis (uc): patient selection and reported outcomes |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007976/ https://www.ncbi.nlm.nih.gov/pubmed/36915649 http://dx.doi.org/10.2147/CEG.S367086 |
work_keys_str_mv | AT iranimalcolm clinicalevaluationofupadacitinibinthetreatmentofadultswithmoderatelytoseverelyactiveulcerativecolitisucpatientselectionandreportedoutcomes AT fanchristopher clinicalevaluationofupadacitinibinthetreatmentofadultswithmoderatelytoseverelyactiveulcerativecolitisucpatientselectionandreportedoutcomes AT glassnerkerri clinicalevaluationofupadacitinibinthetreatmentofadultswithmoderatelytoseverelyactiveulcerativecolitisucpatientselectionandreportedoutcomes AT abrahambincyp clinicalevaluationofupadacitinibinthetreatmentofadultswithmoderatelytoseverelyactiveulcerativecolitisucpatientselectionandreportedoutcomes |